A new cancer drug calls for DNA
Instead of the tumor location in the body
Thursday – 21 Months Spring I 1440 H – November 29, 2018
Drug on mutagenic mutations (Reuters)
New York: Middle East Online
The American Food and Drug Administration (FDA) has approved the introduction of a new anti-cancer drug after testing on patients with lungs, colon, breast, thyroid and other cancers, according to the US website.
The drug has been developed by Loxo Oncology, which acts on cancer mutations, not cancer carcinoma, and can cure cancer from its source and origin to adults and children.
The company set a low cost of $ 132,000 a year for a liquid used to treat children. She also said she would provide financial support to drug-buying patients, which would reduce the daily cost to $ 20 a month for most patients.
On the other hand, Scott Gottlieb, Commissioner of the United States Commissioner, said that "ratifying leave and place this drug is an important step in the treatment of cancer because it is treated from sources, dealing with cancer cancer issues, regardless of the place of origin in the human body."
He stressed that the new drug will help cancer patients receive appropriate therapy.
In 2017, the pharmaceutical company signed a $ 1.5 billion deal with Bayer, a cosmetic giant and the development of two LUXO drugs, including Vitravi.
Genetic mutation is a new method of treating cancer. He did most of the companies involved in the development of treatments for certain types of cancer, such as lung cancer or skin cancer, and initially sought approval only for this type, before further testing to see how the drug works with other types of cancer.
Scientists have seen genetic patterns throughout cancer for years, but the problem began to attract more attention in 2013 after discovering that endometrial cancer is genetically similar to ovarian cancer and breast cancer.